Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM01 monotherapy in relapsed or refractory hematologic malignancies (Phase II, China)
CTR20212227Phase 2Terminated
- Sponsor
- ImmuneOnco
- Start
- Sep 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of timdarpacept in Hodgkin lymphoma (HL), mature B-cell lymphoma, natural killer-cell lymphoma (NK/TCL) and 3 more, sponsored by ImmuneOnco. Primary endpoints: Incidence and characteristics of adverse events (AEs) and serious adverse events (SAEs), Changes from baseline in laboratory tests, physical examination, ECG, and vital signs and 7 more. Started Sep 2021; status: terminated.
02
Drugs
timdarpacept
03
Conditions
Hodgkin lymphoma (HL)mature B-cell lymphomanatural killer-cell lymphoma (NK/TCL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20212227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212227.